ANDA 65171, held by Barr Laboratories. Demeclocycline Hydrochloride.
As of Nov 21, 2026, ANDA 65171 (Demeclocycline Hydrochloride), held by Barr Laboratories, was first approved by FDA on Dec 13, 2004, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2004 | Original application | Approved | None posted |
| Demeclocycline Hydrochloride150MG · tablet;oral | Demeclocycline Hydrochloride | Discontinued |
| Demeclocycline Hydrochloride300MG · tablet;oral | Demeclocycline Hydrochloride | Discontinued |
| Jan 31, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 11, 2012 | Supplement 3Labeling | Approved | None posted |
| Dec 13, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters